CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 5, 2026 10-K/10-Q 八月 6, 2026
$64.27
· % 处于52周区间
· 高于低点
· 至高点
$54.3052周低点
$88.3152周高点
市值
$7.90B
P/E (TTM)
-8.9
EPS (TTM)
$-7.23
收入 (TTM)
$68M
CYTK 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$64.27
市值
$7.90B
P/E (TTM)
-8.9
EPS (TTM)
$-7.23
收入 (TTM)
$68M
ROE (TTM)
329.8%
负债/权益 (MRQ)
-1.6
52周区间
$54–$88
CYTK 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2013年6月25日 | 1-for-6 | 反向 |
关于 Cytokinetics, Incorporated - Common Stock 公司概况（来自维基百科）
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工673
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$88M2016-12-31 → 2025-12-31
EPS$-6.542016-12-31 → 2025-12-31
自由现金流$-535M2016-12-31 → 2025-12-31
净利率-1321.1%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | CYTK | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -8.95年均值 ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 89.85年均值 ≈323.5 | ≈323.5 | 41.9 | 估值过高 | |
| P/B (市净率) | -12.05年均值 ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA (企业价值 / EBITDA) | -13.45年均值 ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF (股价/自由现金流) | -14.85年均值 ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow (市现率) | -15.55年均值 ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue (市值/营收) | 91.65年均值 ≈322.6 | ≈322.6 | · | · | |
| EV / FCF (市值/自由现金流) | -15.15年均值 ≈-16.6 | ≈-16.6 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | CYTK | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -1046.1%5年均值 ≈-2159.0% | ≈-2159.0% | -118.4% | 弱 | |
| 息税折旧摊销前利润率 (TTM) | -1027.6%5年均值 ≈-2113.0% | ≈-2113.0% | -118.4% | 弱 | |
| 净利润率 (TTM) | -1321.1%5年均值 ≈-2357.7% | ≈-2357.7% | -176.2% | 弱 | |
| ROA (TTM) | -56.8%5年均值 ≈-47.8% | ≈-47.8% | -22.9% | 弱 | |
| ROE (TTM) | 329.8%5年均值 ≈322.1% | ≈322.1% | -13.2% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | CYTK | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -1.65年均值 ≈-0.4 | ≈-0.4 | 0.3 | 低负债 | |
| 流动比率 (MRQ) | 6.75年均值 ≈6.7 | ≈6.7 | 5.9 | 持平 | |
| Quick Ratio (速动比率) | 0.75年均值 ≈1.1 | ≈1.1 | 3.6 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | -1.45年均值 ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage (利息保障倍数) | -13.45年均值 ≈-14.6 | ≈-14.6 | -7.7 | 低流动性 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | CYTK | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 376.6%5年均值 ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | -2.4%5年均值 ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 9.5% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | CYTK | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.15年均值 ≈0.1 | ≈0.1 | 0.2 | 弱 | |
| Receivables Turnover (应收账款周转率) | 5.15年均值 ≈4.8 | ≈4.8 | 5.7 | 持平 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$130.8K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-4.4%
下次报告
十一月 03, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| 2026年3月31日 | $-1.67 | $-1.69 | 0.94% | |
| 2025年12月31日 | $-1.50 | $-1.49 | -0.97% | |
| 2025年9月30日 | $-2.55 | $-1.61 | -58.2% | |
| 2025年6月30日 | $-1.12 | $-1.41 | 20.3% | |
| 2025年3月31日 | $-1.39 | $-1.41 | 1.4% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $88M | $18M | $8M | $95M | $70M |
| 营业利润率 % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| 净收入 | $-785M | $-590M | $-526M | $-389M | $-215M |
| 稀释后每股收益 (EPS) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| 流动比率 | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| 速动比率 | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-535M | $-400M | $-416M | $-311M | $-191M |
机构持有人 (13F) 535 家申报者 · $13.2B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
535
持有价值
$13.2B
新仓位
95
已退出持仓
49
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 95 (-11 与上一季度对比) | 49 (-7 与上一季度对比) | 238 (+49 与上一季度对比) | 113 (-29 与上一季度对比) | +10.8M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $1711838738 | 20094362 | 12.99% | 股份 |
| VANGUARD GROUP INC | $765538243 | 12048131 | 5.81% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $590517486 | 6931770 | 4.48% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571778157 | 6711799 | 4.34% | 股份 |
| STATE STREET CORP | $553243709 | 6494233 | 4.20% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $521151103 | 6117515 | 3.95% | 股份 |
| FMR LLC | $428657534 | 5031782 | 3.25% | 股份 |
| Avoro Capital Advisors LLC | $425949915 | 4999999 | 3.23% | 股份 |
| BANK OF AMERICA CORP /DE/ | $394916049 | 4635709 | 3.00% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $316325896 | 3712501 | 2.40% | 股份 |
| RTW INVESTMENTS, LP | $243814036 | 2862003 | 1.85% | 股份 |
| Polar Capital Holdings Plc | $191988358 | 2253649 | 1.46% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161060214 | 1890600 | 1.22% | 买入期权 |
| GOLDMAN SACHS GROUP INC | $150069725 | 1761588 | 1.14% | 股份 |
| Capital Research Global Investors | $143683584 | 1686625 | 1.09% | 股份 |
| NORTHERN TRUST CORP | $140337319 | 1647345 | 1.06% | 股份 |
| JPMORGAN CHASE & CO | $139150046 | 1588895 | 1.06% | 股份 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136597224 | 1603442 | 1.04% | 股份 |
| Integral Health Asset Management, LLC | $136304000 | 1600000 | 1.03% | 股份 |
| Point72 Asset Management, L.P. | $135257185 | 1587712 | 1.03% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133388883 | 1565781 | 1.01% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131998327 | 1549458 | 1.00% | 股份 |
| ARMISTICE CAPITAL, LLC | $130340700 | 1530000 | 0.99% | 买入期权 |
| MORGAN STANLEY | $128664004 | 1510318 | 0.98% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $111740656 | 1311664 | 0.85% | 股份 |
| Capital International Investors | $111245191 | 1305848 | 0.84% | 股份 |
| Invesco Ltd. | $105237167 | 1235323 | 0.80% | 股份 |
| ARMISTICE CAPITAL, LLC | $102342325 | 1201342 | 0.78% | 股份 |
| UBS Group AG | $99781940 | 1171287 | 0.76% | 股份 |
| Pictet Asset Management Holding SA | $99038455 | 1160463 | 0.75% | 股份 |
| Frazier Life Sciences Management, L.P. | $98810092 | 1159879 | 0.75% | 股份 |
| Bank of New York Mellon Corp | $98027901 | 1150697 | 0.74% | 股份 |
| Holocene Advisors, LP | $97506685 | 1144579 | 0.74% | 股份 |
| Woodline Partners LP | $93769315 | 1100708 | 0.71% | 股份 |
| D. E. Shaw & Co., Inc. | $89287894 | 1048103 | 0.68% | 股份 |
| NORGES BANK | $86512319 | 1015522 | 0.66% | 股份 |
| Royalty Pharma Sub-Manager, LLC | $83519594 | 980392 | 0.63% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81937000 | 961815 | 0.62% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $77218175 | 906423 | 0.59% | 股份 |
| CITADEL ADVISORS LLC | $77062874 | 904600 | 0.58% | 买入期权 |
| FRANKLIN RESOURCES INC | $75911721 | 891087 | 0.58% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70521134 | 827810 | 0.53% | 股份 |
| Melqart Asset Management (UK) Ltd | $65385455 | 767525 | 0.50% | 股份 |
| Siren, L.L.C. | $64655121 | 758952 | 0.49% | 股份 |
| Fisher Asset Management, LLC | $63355547 | 743697 | 0.48% | 股份 |
| Foresite Capital Management IV, LLC | $60884867 | 714695 | 0.46% | 股份 |
| Balyasny Asset Management L.P. | $60599821 | 711349 | 0.46% | 股份 |
| Deep Track Capital, LP | $59633000 | 700000 | 0.45% | 股份 |
| JANE STREET GROUP, LLC | $59633000 | 700000 | 0.45% | 买入期权 |
| BNP PARIBAS FINANCIAL MARKETS | $58702470 | 689077 | 0.45% | 股份 |
公司内部人士 52 位内幕人士 · 19 位高管 · 23 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | 2026年9月28日 M | 278544 | 0 | 20 | $-17291957 |
| Sung Lee | EVP, Chief Financial Officer | 2026年7月1日 M | 63221 | 0 | 5 | $-5695855 |
| Ching Jaw | SVP Finance & CFO | 2023年3月6日 A | 87346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 2017年2月28日 F | 40323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 2026年9月22日 M | 153902 | 0 | 21 | $-4654735 |
| Andrew Callos | EVP, Chief Commercial Officer | 2026年8月31日 M | 58555 | 0 | 25 | $-16021293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 2026年3月15日 A | 107943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 2024年12月3日 A | 18655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 2024年8月30日 A | 33140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 2022年3月15日 M | 103408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 2022年3月7日 F | 153233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 2018年2月27日 A | 32548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 2018年2月27日 A | 21520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 2017年8月31日 M | 46441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 2017年2月28日 A | 29004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 2017年2月28日 A | 47255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 2011年2月28日 A | 42000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 2009年12月18日 M | 20043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 2008年2月29日 A | 47896 | 0 | 0 | $0 |
| Robert E Landry | 董事 | 2026年9月15日 S | 8184 | 0 | 2 | $-146790 |
| Lynne B Parshall | 董事 | 2026年9月1日 S | 10784 | 0 | 4 | $-1357500 |
| Robert Arthur Harrington | 董事 | 2026年7月15日 A | 21932 | 0 | 1 | $-143620 |
| James M Daly | 董事 | 2026年7月15日 A | 3390 | 0 | 0 | $0 |
| Edward M. Kaye MD | 董事 | 2026年7月15日 A | 10434 | 0 | 4 | $-2837811 |
| Nancy Wysenski | 董事 | 2026年7月15日 A | 33992 | 0 | 0 | $0 |
| Wendell Wierenga | 董事 | 2026年7月15日 A | 35563 | 0 | 3 | $-1881925 |
| John T Henderson | 董事 | 2026年7月15日 A | 78360 | 0 | 2 | $-2078525 |
| Muna Bhanji | 董事 | 2026年5月27日 A | 26361 | 0 | 0 | $0 |
| Wendall Wierenga | 董事 | 2025年7月15日 A | 32345 | 0 | 0 | $0 |
| COSTA SANTO J | 董事 | 2024年5月15日 A | 20600 | 0 | 0 | $0 |
| Sandford D Smith | 董事 | 2024年1月2日 A | 18801 | 0 | 0 | $0 |
| Robert Califf | 董事 | 2022年1月3日 A | 6003 | 0 | 0 | $0 |
| GAGE L PATRICK | 董事 | 2021年11月8日 M | 28932 | 0 | 0 | $0 |
| Denise Gilbert | 董事 | 2015年5月20日 J | · | 0 | 0 | $0 |
| Stephen M Dow | 董事 | 2013年1月2日 A | 1421052 | 0 | 0 | $0 |
| James A Spudich | 董事 | 2011年5月18日 A | 180600 | 0 | 0 | $0 |
| Grant A Heidrich III | 董事 | 2011年1月3日 A | 93755 | 0 | 0 | $0 |
| Michael Schmertzler | 董事 | 2010年6月3日 S | 4340923 | 0 | 0 | $0 |
| Mark Mcdade | 董事 | 2009年5月21日 A | · | 0 | 0 | $0 |
| Charles J Homcy | 董事 | 2008年5月22日 A | · | 0 | 0 | $0 |
| William J Rutter | 董事 | 2004年4月29日 C | 172413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10% 所有者 | 2004年4月29日 C | 1615716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10% 所有者 | 2004年4月29日 C | 771052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10% 所有者 | 2004年4月29日 C | 650000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10% 所有者 | 2004年4月29日 C | 755631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | 2017年2月28日 A | 43919 | 0 | 0 | $0 |
| James H Sabry | · | 2010年6月3日 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | 2004年4月29日 C | 24050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | 2004年4月29日 C | 625950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | 2004年4月29日 C | 1742951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | 2004年4月29日 C | 15421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | 2004年4月29日 C | 127235 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 54 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.51% | 19346 NS | 2026年7月31日 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0.81% | 882597 SH | 2026年10月2日 | 每日 |
| LABU · Direxion Shares ETF Trust | 0.79% | 50312 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 0.73% | 1020305 SH | 2026年9月11日 | 每日 |
| FNY · First Trust Exchange-Traded Alpha... | 0.72% | 53872 NS | 2026年7月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.64% | 107023 NS | 2026年7月31日 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.64% | 102933 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.61% | 9831 SH | 2026年10月2日 | 每日 |
| IQSM · New York Life Investments ETF Trust | 0.35% | 14748 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.34% | 761130 SH | 2026年8月19日 | 每日 |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.33% | 72343 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.33% | 63327 NS | 2026年7月31日 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.32% | 1797986 SH | 2026年8月19日 | 每日 |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.32% | 219413 SH | 2026年8月19日 | 每日 |
| IWM · iShares Trust | 0.32% | 3378753 SH | 2026年9月11日 | 每日 |
| IVOV · VANGUARD ADMIRAL FUNDS | 0.31% | 53623 SH | 2026年8月19日 | 每日 |
| ISCG · iShares Trust | 0.30% | 39366 SH | 2026年9月11日 | 每日 |
| PTMC · Pacer Funds Trust | 0.29% | 14892 NS | 2026年7月31日 | N-PORT |
| FNX · First Trust Exchange-Traded Alpha... | 0.27% | 48364 NS | 2026年7月31日 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.24% | 20179 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.23% | 88671 SH | 2026年9月11日 | 每日 |
| MIDU · Direxion Shares ETF Trust | 0.22% | 1994 NS | 2026年7月31日 | N-PORT |
| PWS · Pacer Funds Trust | 0.22% | 687 NS | 2026年7月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.22% | 16176 NS | 2026年7月31日 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund ... | 0.21% | 54306 NS | 2026年7月31日 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.20% | 15469 NS | 2026年7月31日 | N-PORT |
| SMDX · Tidal Trust III | 0.19% | 3254 NS | 2026年7月31日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.17% | 40586 SH | 2026年8月19日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.14% | 3113794 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.14% | 333056 SH | 2026年8月19日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.13% | 1557779 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.12% | 52671 NS | 2026年7月31日 | N-PORT |
| ESSC · Strategy Shares | 0.10% | 466 NS | 2026年7月31日 | N-PORT |
| WSML · iShares Trust | 0.09% | 7841 SH | 2026年9月11日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.07% | 15233 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.07% | 133196 SH | 2026年9月11日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.07% | 27265 SH | 2026年10月2日 | 每日 |
| TILT · FlexShares Trust | 0.02% | 5740 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 4315260 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 10880 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.02% | 29174 SH | 2026年8月19日 | 每日 |
| IUSG · iShares Trust | 0.01% | 64511 SH | 2026年9月11日 | 每日 |
| IUSV · iShares Trust | 0.01% | 53197 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.01% | 180021 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.01% | 36083 SH | 2026年9月10日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.01% | 106638 SH | 2026年8月19日 | 每日 |
| RWK · Invesco Exchange-Traded Fund Trus... | 0.00% | 478 SH | 2026年9月29日 | 每日 |
| IJH · iShares Trust | · | 4763860 SH | 2026年9月11日 | 每日 |
| IJK · iShares Trust | · | 425186 SH | 2026年9月11日 | 每日 |
| IJJ · iShares Trust | · | 318457 SH | 2026年8月21日 | 每日 |
| IWN · iShares Trust | · | 1107696 SH | 2026年9月11日 | 每日 |
| XJH · iShares Trust | · | 18548 SH | 2026年9月8日 | 每日 |
| ISCB · iShares Trust | · | 5565 SH | 2026年9月11日 | 每日 |
| SMLF · iShares Trust | · | 71881 SH | 2026年9月11日 | 每日 |
CYTK 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 28 位分析师
买入
中位数目标
$107.50
+67.3%
6 21.4%
强烈买入
19 67.9%
买入
3 10.7%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
20 位分析师 · 2026-09-29平均目标 $109.90 +71.0%
← 低于所有目标
当前价格 $64.27
最低$85.00
平均值$109.90
最高$146.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报